Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$7.48
-0.3%
$6.58
$4.25
$9.85
$2.77B0.412.69 million shs1.88 million shs
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$129.46
$128.90
$73.04
$129.65
$8.36B0.891.55 million shsN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$17.89
+2.3%
$15.00
$8.02
$18.08
$8.89B1.665.47 million shs6.72 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$11.92
+0.9%
$11.42
$8.73
$13.06
$8.10B1.155.77 million shs4.90 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
-1.32%-0.27%+14.87%+68.24%+28.67%
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
0.00%0.00%0.00%+27.55%+36.59%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+0.37%-2.70%+16.97%+38.24%+17.80%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+0.77%+0.51%+2.70%+8.65%+0.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
4.3441 of 5 stars
2.04.00.04.03.83.31.3
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
0.5049 of 5 stars
2.10.00.00.00.00.80.6
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
3.1498 of 5 stars
2.42.00.00.33.41.71.3
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3.4721 of 5 stars
3.63.00.00.04.23.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
2.00
Hold$9.0020.30% Upside
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
2.11
Hold$130.000.42% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.78
Moderate Buy$17.33-3.13% Downside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3.25
Buy$16.5038.42% Upside

Current Analyst Ratings Breakdown

Latest BHC, BPMC, ELAN, and ROIV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/11/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$12.00 ➝ $18.00
8/8/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$18.00 ➝ $19.00
7/23/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$17.00 ➝ $18.00
7/17/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/17/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$18.00
7/10/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$19.00
7/2/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $17.00
6/26/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
6/18/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
6/17/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$143.00 ➝ $129.00
(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$9.86B0.28$7.63 per share0.98$0.40 per share18.70
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$562.12M14.87N/AN/A$4.70 per share27.54
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B2.00$2.31 per share7.75$13.64 per share1.31
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.05M278.94N/AN/A$7.08 per share1.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
-$46M$0.2628.771.61N/A0.99%-852.36%5.25%10/29/2025 (Estimated)
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$67.09M-$2.47N/A199.17N/A-27.70%-64.60%-17.22%10/28/2025 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.8620.8120.103.249.68%7.04%3.45%11/6/2025 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%N/A

Latest BHC, BPMC, ELAN, and ROIV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.1989$0.26+$0.0611$0.02$1.19 billion$1.24 billion
7/30/2025Q2 2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$0.97$0.90-$0.07$0.40$2.47 billion$2.57 billion
5/29/2025Q4 2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/AN/AN/AN/AN/A
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
141.90
1.31
0.98
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.01
2.80
2.75
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.61
2.60
1.40
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
40.54
40.54

Institutional Ownership

CompanyInstitutional Ownership
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
78.65%
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%

Insider Ownership

CompanyInsider Ownership
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
8.05%
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
4.21%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20,700370.13 million340.33 millionOptionable
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
64064.58 million61.86 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.81 million492.39 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860679.81 million606.39 millionOptionable

Recent News About These Companies

Roivant Sciences (NASDAQ:ROIV) Shares Gap Down After Earnings Miss
An Overview of Exact Sciences's Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bausch Health Cos stock logo

Bausch Health Cos NYSE:BHC

$7.48 -0.02 (-0.25%)
Closing price 03:59 PM Eastern
Extended Trading
$7.72 +0.24 (+3.26%)
As of 05:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Blueprint Medicines stock logo

Blueprint Medicines NASDAQ:BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$17.89 +0.40 (+2.30%)
Closing price 03:59 PM Eastern
Extended Trading
$17.85 -0.04 (-0.24%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$11.92 +0.11 (+0.93%)
Closing price 04:00 PM Eastern
Extended Trading
$11.78 -0.14 (-1.17%)
As of 05:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.